Veristrat

From Wikipedia, the free encyclopedia
Jump to: navigation, search

Veristrat is a test aiming at predicting benefit from canceer treatment by EGFR inhibitors. It is a serum/plasma proteomic test developed using matrix-assisted laser desorption/ionization (MALDI) mass spectrometry.

The VeriStrat algorithm has been interrogated retrospectively and prospectively in samples from randomised trials, such as the PROSE study, confirming the prognostic information associated with the molecular signature. In addition, the test appeared to be predictive of erlotinib impact on survival, as only "VeriStrat Good patients" benefited from such a treatment. Additional studies should confirm and further define its role in predicting EGFR inhibitors benefit.[1]

References[edit]

  1. ^  edit